Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The efficacy of ruxolitinib re-treatment in patients with MF

Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, shares some insights into the safety and efficacy of re-treating patients with ruxolitinib as an alternative treatment approach in myelofibrosis (MF). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.


Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie